Johnson & Johnson on Tuesday said it would delay the rollout of its vaccine in Europe amid concerns over rare blood clots, in another blow to the continent’s ambition to ramp up inoculation campaigns that have lagged behind other countries in the West.
Several countries of the bloc were poised to start administering the vaccine later this week, in what would have been a boost to efforts by the European Union to vaccinate 70 percent of adults by September.
“The safety and well-being of the people who use our products is our number one priority,” Johnson & Johnson said in a statement, adding that it had been reviewing the cases of blood clots detected in the United States with European health authorities.
The first signs of concern in Europe came last week. The European Medicines Agency, the bloc’s drug regulator, said it was investigating reports of four cases of blood clots in people who had received a shot of Johnson & Johnson’s Janssen vaccine in the United States, one of them being fatal. The regulator said it wasn’t clear if there was a link between the vaccine and the clots, adding that it treated the reports as “safety signal” that required further assessment.
Johnson & Johnson’s single-dose coronavirus vaccine came to a sudden halt in much of the United States on Tuesday after federal health agencies called for a pause in the vaccine’s use following the emergence of a rare blood clotting in six recipients.
All six were women between the ages of 18 and 48 and all developed symptoms within about two weeks of vaccination. One woman died and a second woman in Nebraska has been hospitalized in critical condition.
Nearly seven million people in the United States have received Johnson & Johnson shots so far, and about nine million more doses have been shipped out to the states, according to data from the Centers for Disease Control and Prevention.
Johnson & Johnson’s announcement comes as Europe has been embroiled in a regulatory back-and-forth over another vaccine, AstraZeneca’s. Several countries have restricted the use of the vaccine in younger people, after the European Medicines Agency said there was “a possible link” between blood clots and the vaccine earlier this month, and said it should be listed as a rare side effect.